Related Experiment Video
Updated: Mar 13, 2026
09:35
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
14.1K
Hepatitis B virus inhibits apolipoprotein A5 expression through its core gene
Chengliang Zhu1, Guosheng Gao2, Hui Song3
1Department of Clinical Laboratory, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, People's Republic of China.
Lipids in Health and Disease
|October 12, 2016
Summary
Hepatitis B virus (HBV) infection lowers apolipoprotein A5 (ApoA5) levels. HBV
Area of Science:
- Hepatology and Virology
- Molecular Biology
- Biochemistry
Background:
- Hepatitis B virus (HBV) infection is linked to disruptions in lipid metabolism.
- Apolipoprotein A5 (ApoA5) is a key regulator of lipid metabolism.
- The precise impact of HBV on ApoA5 expression requires elucidation.
Purpose of the Study:
- To investigate the effect of HBV on ApoA5 expression.
- To explore the molecular mechanisms underlying HBV-mediated regulation of ApoA5.
Main Methods:
- Quantitative assessment of ApoA5 mRNA and protein levels using RT-PCR and Western blotting.
- Measurement of serum ApoA5 concentrations via ELISA in HBV patients and healthy controls.
- Luciferase reporter assays to evaluate ApoA5 promoter activity following HBV transfection.
Main Results:
- ApoA5 mRNA and protein expression were significantly reduced in HBV-infected HepG2.2.15 cells compared to control HepG2 cells.
- Serum ApoA5 levels were markedly lower in HBV patients (104.5 ± 18.3 μg/L) than in healthy individuals (196.4 ± 28.7 μg/L).
- HBV, particularly its core gene, suppressed ApoA5 promoter activity and expression at both transcriptional and translational levels.
Conclusions:
- Hepatitis B virus significantly downregulates ApoA5 expression.
- HBV's core gene plays a crucial role in inhibiting ApoA5 at transcriptional and translational levels.
- These findings highlight a novel mechanism by which HBV disrupts lipid metabolism.
Related Concept Videos
01:16Hepatic Drug Excretion: Influencing Factors
704
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
704
01:29Viruses with RNA Genomes
1.2K
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
1.2K
01:09Hepatic Drug Clearance: Effect of Protein Binding
648
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
648
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
309
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
309
01:52Eukaryotic Transcription Inhibitors
11.2K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.2K
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
320
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
320